Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.